Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.18 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in hepatic stellate cells | 0.75 |
| chemistry Open Targets | compounds already reach it: jnj-18038683, zimeldine hydrochloride, dexfenfluramine +4 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 157 | 0.82 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2080
Sealed predictions
- HTR7 in dopamine neurons, braak+0.16 (p 0.689) → -0.26 (p 0.502)receipt 2088
Swarm cases
receipt 2088: HTR7 in dopamine neurons, braak
- power
- full sample -0.10 (p 0.696, n 18), 95% CI -0.54 to +0.39. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.05 (p 0.834, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.12 (p 0.627, n 18). could be the mix.
- skeptic
- leave-one-out range -0.24 to +0.02, sign flips 1; without severely affected donors -0.10 (p 0.696, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for HTR7 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts